These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 31805962)

  • 1. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
    Lang L; Shay C; Xiong Y; Thakkar P; Chemmalakuzhy R; Wang X; Teng Y
    J Hematol Oncol; 2018 Jun; 11(1):85. PubMed ID: 29925404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib.
    Lang L; Lam T; Chen A; Jensen C; Duncan L; Kong FC; Kurago ZB; Shay C; Teng Y
    Cells; 2020 Feb; 9(3):. PubMed ID: 32106632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
    Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
    Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
    Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
    Wang L; Yu X; Dong J; Meng Y; Yang Y; Wang H; Wang C; Zhang Y; Zhao Y; Zhao J; Wang H; Lu C; Li B
    Biochem Biophys Res Commun; 2016 Oct; 479(3):563-570. PubMed ID: 27666484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
    Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
    Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.